In China and other parts of the world, hospital personnel adherence to evidence-based stroke care is limited.
T he overall global burden of stroke has increased in the past several decades in developing countries. 1 Stroke is the leading cause of death and adult disability in China, 2 with an estimated 2.4 million new stroke events in 2013. 3 Largescale randomized trials and systematic reviews have established the efficacy of several performance measures for acute ischemic stroke, such as intravenous recombinant tissue plasminogen activator (rtPA or alteplase), antiplatelet therapy, and anticoagulation for patients with atrial fibrillation. 4 ,5 However, adherence to these evidence-based performance measures is suboptimal and gaps in adherence to guidelinerecommended care are even greater in China. 6 Multifaceted quality improvement interventions that address the barriers to care are effective in changing physician practices.
7-9 Quality improvement interventions have demonstrated that stroke care quality can be improved by conducting interventions such as using clinical pathways, training physicians on evidence-based guidelines, auditing care delivery, and providing timely feedback. 10,11 Nevertheless, previous cluster-randomized studies in this area have had conflicting results. Some studies have demonstrated significant improvements in health care quality from quality improvement interventions, 12,13 whereas others have found no significant effect. 14,15 However, to our knowledge, randomized clinical trials have not been used to assess the effectiveness of multifaceted quality improvement interventions of stroke care in developing countries, which have up to 78% of the global burden of stroke. 1 Furthermore, the effect of these process improvement interventions on short-term or long-term clinical outcomes needs to be explored further. Therefore, a cluster-randomized clinical trial called Intervention to Bridge the Evidence-based Gap in Stroke Care Quality (GOLDEN BRIDGE-AIS) was conducted to examine the effectiveness of a multifaceted quality improvement intervention on hospital personnel adherence to evidence-based performance measures and outcomes in patients with acute ischemic stroke (AIS) in China.
Methods

Study Design
Details of this trial's design and methods have been published elsewhere and in Supplement 1. 16 Briefly, this trial was an open-label, cluster-randomized clinical trial. The main aims were to evaluate the effect of a multifaceted quality improvement intervention on adherence to evidence-based performance measures for patients with AIS during the acute phase of care and at discharge and patient outcomes such as new vascular events, disability, and mortality at 3, 6, and 12 months after stroke onset. The trial protocol was approved by the central institutional review board at Beijing Tiantan Hospital. In addition, all participating clusters received the approval by their local research ethics board. Written consent was obtained at the cluster (hospital)-level from the hospital medical director. Consent was also obtained from patients or their proxy for participation in a telephone survey at 3, 6, and 12 months after the initial stroke. The formal patient enrollment period was 
Hospitals
Hospitals were enrolled from the China National Network of Stroke Research (now the Chinese Stroke Center Alliance). The Chinese Stroke Center Alliance, established by the National Center of Quality Management in Neurological Diseases Care (formerly the National Center of Quality Management in Stroke Care), includes 563 hospitals from 27 provinces and 4 municipalities (total 31 locations) in Mainland China. In China, hospitals are classified into 3 grades: community hospitals are defined as primary grade, hospitals that serve several communities are defined as secondary grade, and central hospitals for a certain district or city are defined as tertiary grade. 17 Hospital regions are divided into eastern, central, and western areas according to the annual report on health statistics of China. 18 Only secondary or tertiary public hospitals with emergency departments (EDs) and neurological wards that admit patients with stroke and had the capacity to administer intravenous rtPA were eligible to participate in this trial. Primary hospitals, private hospitals, and hospitals in rural regions were excluded.
and control groups at each hospital, and obtain a reliable estimation of the sample size. Methods and results of this baseline survey were presented in eAppendix A in Supplement 2.
Cluster Randomization and Blinding
Forty eligible hospitals were randomly selected and stratified by the following characteristics: province, hospital capacity (secondary grade or tertiary), and baseline level of stroke care quality. This was done by an independent statistician not otherwise involved in the study. These clusters were randomized 1:1 to a multifaceted quality improvement intervention (intervention group) or routine care plus stroke registry participation (control group) by using a randomly generated number (SAS [SAS Institute], version 9.3 software). Given the nature of the multifaceted intervention, only the independent outcome evaluators and statisticians were blinded to the intervention.
Stroke Quality Improvement Interventions
The multifaceted quality improvement intervention included an evidence-based clinical pathway, written care protocols for implementation of performance measures, a full-time quality coordinator, and a monitoring and feedback system for performance measures. Two physicians from each of the intervention clusters (the director of the department of neurology acting as a local investigator and a physician or nurse acting as a quality coordinator) attended a 2-day workshop designed to educate the hospital personnel on this trial about quality improvement intervention. These 2 trained professionals took charge of sharing these operational methods with cluster personnel who took care of patients with stroke. The evidence-based clinical pathway was written by a panel of stroke experts according to the published statements in peer-reviewed literature, consensus statements and guidelines. 5, 19 It was integrated into the care plan of each eligible stroke admission. This pathway consisted of general guideline-based recommendations for acute stroke management, and a specific daily care plan for each of the first 7 days of the acute admission and discharge. Written care protocols for the implementation of performance measures were provided for all intervention clusters, and included the following: intravenous rtPA protocol; a deep venous thrombosis (DVT) prophylaxis protocol; a swallowing dysfunction management protocol; evidence-based medications protocols for antithrombotic therapy after admission and at discharge; anticoagulation for patients with atrial fibrillation; guidelines for prescribing statin medications; and guidelines for prescribing antihypertensive and hypoglycemic medications when appropriate.
A trained physician or nurse in each intervention cluster acted as a quality coordinator. The responsibility of the quality coordinator included interacting with physicians once gaps in the application of evidence-based interventions were identified, ensuring that all components of the quality improvement intervention were implemented for patients with AIS, identifying barriers to the implementation, and training the health care staff involved with the care of the patients.
A monitoring and feedback system, as well as a cyclical model of predefined performance measures, was designed to automatically analyze and provide feedback to the team providing quality stroke care in the intervention group. An independent quality management account was assigned to the quality coordinator of all of the intervention clusters to log in to the monitoring and feedback system. The intervention cluster's investigators or quality coordinator were required to check their level of adherence to the predefined performance measures at least once a week and compare the observed performance with performance measured to-date and performance by other clusters.
Data Collection
In all participating clusters, data were obtained prospectively and entered into a web-based data entry system by a local, trained independent research coordinator who was not involved in the care of patients and received compensation from this trial. Range checks were used to check for inconsistent or out-of-range data and prompted the user to correct or review data entries outside the predefined range. The system also provided predefined logic checks to identify errors or illogical data entries. A data quality meeting was held monthly to review all the hospital enrollment records and registry data.
Outcomes
The primary outcomes were adherence to the 9 predefined evidence-based performance measures in patients with AIS, 6 of which were designed to be the same as the Get With The Guidelines-Stroke (GWTG-Stroke) performance measures.
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These included 4 performance measures at the beginning of hospitalization (intravenous rtPA treatment within 3 hours of symptom onset, early use of antithrombotics, dysphagia screening, and DVT prophylaxis) and 5 performance measures at discharge (use of antithrombotics, anticoagulation for patients with atrial fibrillation or flutter, use of a lipid-lowering agent for lowdensity lipoprotein [LDL] of more than 100 mg/dL or undocumented LDL [to convert to mmol/L, multiply by 0.0259], use of antihypertension medication, and treatment of diabetes). Detailed performance measure specifications and contraindications are shown in eTable 1 in Supplement 2.
Adherence was expressed as an all-or-none measure or a composite measure as co-primary outcomes if either one was statistically significant, the study was to be interpreted as "positive." The all-or-none measure was defined as the proportion of patients who received all of the performance measures for which the patient was eligible. The composite measure was defined as the total number of eligible performance measures performed divided by the total number of performance measures for which a given patient was eligible. The composite measure was calculated for each patient and then averaged.
The secondary outcomes included in-hospital death, a new clinical vascular event (ischemic stroke, hemorrhagic stroke, myocardial infarction, or vascular death), disability as measured by modified Rankin Scale (mRS; score of 3-5); and allcause mortality at 3, 6, and 12 months after initial symptom onset. Trained research personnel were blinded to the intervention and used standardized scripts to contact patients or caregivers by telephone at 3, 6, and 12 months. 16 Symptomatic intracerebral hemorrhage was recorded in patients treated with intravenous rtPA. Symptomatic intracerebral hemorrhage was defined as any type of intracerebral hemorrhage on any posttreatment imaging related to any worsening in neurological condition. 20 
Sample Size
A prerandomization survey at participating clusters was conducted. The mean composite score of stroke care quality was 80%. According to the GWTG-Stroke program, the guideline adherence to individual performance measures was increased 4.33% from baseline (83.52%) to the first year after the implementation (87.85%) of GWTG-Stroke. 10 Therefore, a total of 4800 patients at 40 hospitals (considering a median of 120 patients with AIS per hospital) would be required to detect a 5% improvement in the composite evidence-based performance measures in patients with AIS, with 80% power, 5% significance level, and an intracluster correlation coefficient (ICC) of 0.02. 10 According to this predefined sample size, each group was required to enroll 2400 patients. The web-based patient management tool was used to enter patient's data and monitor the enrollment number of patients. When 2400 eligible patients were recruited for a group, the enrollment for that group was stopped.
Data Analysis
We used intention-to-treat analysis for all outcomes. 21 The baseline characteristics of hospitals and patients were analyzed to assess cluster differences between intervention and control groups. We summarized continuous variables as median with interquartile ranges and categorical variables as frequency and percentage. We analyzed continuous and categorical data by using Wilcoxon rank-sum test and χ 2 test separately. 16 With all comparative outcomes, cumulative incidences and absolute differences with 95% CIs were presented and adjusted by patient and hospital baseline characteristics. Modes were used to impute missing values of categorical variables, and medians were imputed for missing values of continuous variables. Smoking status had the highest proportion of missing values at 1.42%, which were replaced with the value of no smoking history. Only one patient had a missing National Institutes of Health Stroke Scale (NIHSS) score, which was replaced by the median value of 3.
Multivariable regression models were performed to compare the outcomes between intervention and control groups. Generalized estimating equations were used to account for within-hospital correlation. Logistic regression was performed for the binary all-or-none measure and disability outcomes. The composite measure was expressed as the odds of fulfilling care opportunities for which a patient was eligible. Thus in the analysis of the composite measure, each care opportunity contributed an observation in the analysis, and the outcome was a dichotomized (1 = measure met vs 0 = measure not met). 6, 10 For example, if a particular patient was eligible for 5 of the 7 performance measures and only received 3 of them, this patient contributed 5 observations to the analysis; 3 of the measures would have an outcome value of 1 and 2
would have an outcome value of 0. The effects of intervention were expressed as a population average odds ratio (OR PA ).
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The clinical vascular events and mortality at discharge and at 3, 6, and 12 months after initial symptom onset were analyzed as time-to-event outcomes. A mixed-model with a binary link function was used for 3-, 6-, and 12-month disability. These outcomes were demonstrated by Kaplan-Meier curves and assessed by using multivariable Cox proportional hazards models. To assess that the improvement in performance measure compliance in the intervention group was not due to the increased documentation of contraindications (smaller denominator not larger numerator), a sensitivity analysis that included patients with contraindications for evidencebased interventions in the denominator of the overall population was conducted. All multivariable models adjusted for patient characteristics (including age, sex, history of ischemic stroke, hypertension disease, diabetes, hyperlipidemia, atrial fibrillation, coronary artery disease and previous myocardial infarction, ever smoking, and NIHSS score at admission) and hospital characteristics (including hospital capacity [tertiary and secondary], region, stroke unit, teaching hospital status, and number of neurological ward beds). There was no adjustment multiple comparison for co-primary outcome measures. All secondary analyses were interpreted to be exploratory. A P value less than .05 was considered statistically significant; all tests were 2-sided. All statistical analyses were performed by using SAS (SAS Institute), version 9.3.
Results
A total of 40 hospitals from 18 provinces were initially recruited into the trial. Three hospitals, which had unexpected inability to conduct this trial, were replaced according to their characteristics. Finally, 40 hospitals were included. A total of 4800 patients were enrolled prospectively and included in the primary analysis ( Figure 1) . None of the clusters were further excluded from this trial. The duration of enrolling patients was 207 days (interquartile range [IQR] , 182-225) in the intervention group and 204 days (IQR, 159-262) in the control group. Table 1 shows the characteristics of patients and hospitals in the baseline survey and intervention and control groups. The mean age of the patients enrolled was 65 years and 36.6% were women. From these participating hospitals, 72.5% were tertiary hospitals, 62.5% had a stroke unit, 62.5% were teaching hospitals, and the median annual number of beds of neurological wards was 77 (IQR, 61-178). The mean number of patients in each cluster was 120 (range, 102-145). Patient and hospital characteristics were balanced between intervention and control groups except for length of stay. There were 2003 patients (83.5%) in the intervention group and 1977 patients (82.4%) in the control group who completed 12-month follow-up. Baseline characteristics of patients with and without the 1-year mRS measurement are shown in eTable 2 in Supplement 2.
Adherence to Evidence-Based Performance Measures
In the intervention group, the median time interval between monitoring of the AIS performance measures and subsequent feedback was 7 days. Adherence to evidence-based performance measures is summarized in Table 2 ). Although the adherence to each of the 9 performance measures was higher in intervention hospitals than that in control hospitals, there were no statistically significant differences at the individual measure level except for 2 performance measures: DVT prophylaxis and antidiabetic medication. Figure 2A ). Stroke disability was also lower in the intervention group than the control group for each time point (intervention group vs control group: 3 months, 19.2% vs 21.0% [absolute difference, −3.72% {95% CI, −6.7% to −0.79%}, odds ratio {OR}, 0.76 {95% CI, 0.63 to 0.91}]; 6 months, 15.8% vs 17.9% [absolute difference, −3.86% {95% CI, −6.60% to −1.13%}, OR, 0.74 {95% CI, 0.61 to 0.89}]; and 12 months, 12.7% vs 14.7% [absolute difference, −3.13% {95% CI, −5.80% to −0.46%}, OR, 0.74 {95% CI, 0.59 to 0.93}]). There was no significant difference in total mortality rates in the hospital and at 3, 6, and 12 months ( Figure 2B ). Symptomatic intracerebral hemorrhage in patients receiving intravenous rtPA did not differ significantly between the intervention and control groups (2.2% [1 of 46 patients] in the intervention group vs 8.7% [2 of 23 patients] in the control group, P = .26).
Clinical Events
Sensitivity Analysis
A sensitivity analysis, which included patients with contraindications for evidence-based interventions in the denominator of the overall population, was conducted. The composite measure remained higher in the quality improvement intervention group than the control group (85.3% in the intervention group vs 80.91% in the control group [absolute difference, 4.20% {95% CI, 1.77% to 6.63%}, adjusted OR PA , 1.36 {95% CI, 1.11 to 1.67}; P = .003]), shown in eTable 4 in Supplement 2.
Discussion
In this cluster-randomized clinical trial, a multifaceted quality improvement intervention was effective in improving the quality of acute stroke care in public hospitals in China. These quality improvement interventions significantly improved short-term and long-term outcome in reductions of new vascular events and reduced stroke disability.
This study focused on improving the quality of care for patients admitted to public hospitals in China who have fewer resources and lower personal income than patients represented in prior studies from Western Europe and the United States.
12,13 Public hospitals are the main source of physicians, accounting for 92% of hospital admissions in China. 22 These public hospitals are overcrowded with patients and have limited resources. These findings suggest that despite these limitations, quality improvement interventions are feasible and could still be successful. Furthermore, these interventions are simple and do not require expensive technology or complex medical intervention. However, except for DVT prophylaxis and antidiabetic medication at discharge, the differences at the level of each individual performance measure between the 2 groups did not reach significance. These findings do not imply that the multifaceted intervention tools only worked on these 2 performance measures: DVT prophylaxis and antidiabetic medication at discharge. The performance on the all-or-none measure was not better in the hospitals receiving quality improvement intervention in this trial. In the all-or-none measure, no credit is given for patients who receive some, but not all, required performance measures. 23 Longer-lasting interventions might be needed to identify a significant difference in the all-or-none measure. This study identified that this multifaceted quality improvement intervention was effective and workable in clinical settings in China to increase hospital personnel adherence to evidence-based performance measures of stroke care and decrease the short-term and long-term rates of new vascular events and disability among patients with AIS. A part of these findings is consistent with those of large, stroke care quality improvement registries, such as American Heart Association/ American Stroke Association's GWTG-Stroke.
10,11 The GWTGStroke program worked with participating hospitals and implemented these guidelines by providing quality improvement consultation, workshops, and webinars. GWTG-Stroke is also supported by a web-based patient management tool not only for data collection, but also for providing decision support and real-time online reporting. 11 Significant improvements in the quality of care were observed from 2003 to 2009 with a composite measure improvement from 83.52% to 93.97%. 24 In the national quality improvement initiative Target: Stroke, which employed 10 key evidence-based strategies, the results were convincing: improved timeliness of intravenous rtPA administration following AIS on a national scale with associated improvements in clinical outcomes. 25 However, both GWTG-Stroke and Target: Stroke projects were not randomized clinical trials, which may lead to overestimation of the effect of the intervention. A cluster-randomized trial design can better evaluate the effect of the quality improvement intervention on care and outcomes while minimizing potential biases.
9,26
Previous cluster-randomized studies of AIS that utilized different quality improvement tools showed mixed results. The Project for the Improvement of Stroke Care Management in Minnesota (PRISMM) failed to identify a quality improvement intervention effect in care. Only 5 of 10 performance measures were the same with those in this trial. The quality improvement tools were also different from those in this trial. In particular, control hospitals in the PRISMM study also received audit and written feedback of baseline performance, which helped to improve quality.
14 However, cluster-randomized studies demonstrated that clinical pathways can significantly increase evidence-based management procedures, such as early aspirin prescription and dysphagia screen. 12,27 Implementation of standardized discharge orders after stroke is also associated with improved optimal secondary stroke prevention. 15 The Increasing Stroke Treatment Through Interventional Behavioral Change Tactics (INSTINCT) trial used a multifaceted intervention, such as a clinical practice guideline promotion, telephone support for treatment decisions, and audit and feedback mechanisms. The trial demonstrated significant improvement in the use of alteplase in eligible patients. 13 It is possible that the frequency of measuring quality indicators might have influenced the quality of stroke care. Physicians may improve their behavior in response to their awareness of being observed, a phenomenon known as the Hawthorne effect, 28 which may be a part of the quality improvement initiative intervention. There were several important considerations incorporated in this trial. A cluster-randomized design reduced the likelihood of contamination between intervention and control groups of the trial. Concealed allocation and blind adjudication of outcomes were used to avoid bias. 29 The use of intention-to-treat principles prompted the use of a cluster design to minimize the risk of biased selection of reporting of the outcomes. In addition, the data were collected by trained independent research coordinators at each hospital who were independent of the care processes. The HR curves of these new clinical vascular events were almost completely separated in the first 30 days. Adherence to secondary stroke prevention therapy can reduce cardiovascular events as identified in the randomized trials and by recommended international guidelines. 4, 5, 19, 30 Meanwhile, other findings included that the long-term disability was lower in the intervention group than that in the control group, which may contribute to the decrease of new clinical vascular events, especially recurrent stroke. Evidently, the favorable outcomes associated with increased adherence to evidence-based performance measures should be interpreted with caution. In these findings, the clinical effect size is much greater than the process effect size. One possible explanation of this observation is that the intervention itself may have improved overall stroke care, not just the process measures. Patient benefit from the intervention may be only partially captured by improved process measures. In addition, the significant effect of the intervention was preserved when a sensitivity analysis did not exclude any patients with a documented contraindication, suggesting that the benefit was due to more patients getting the intervention rather than more documentation of exclusions. 
Limitations
This trial had several limitations. First, the difference of composite score between the 2 groups is 3.4%, which was smaller than the minimal detectable differences used in the power analysis (5% improvement). Second, those hospitals enrolled from the China National Network of Stroke Research may be more motivated and have greater access to resources to improve stroke care quality than other hospitals. Further studies will be necessary to determine the effect of this quality improvement intervention in hospitals in China that differ in characteristics from those that participated. Third, the quality improvement intervention was studied over an 11-month period and additional study is needed to determine whether improvement in stroke care would continue over a longer period and whether differences in mortality may emerge with follow-up beyond 1 year. Fourth, the selected quality improvement measures in this trial were limited to medical management of stroke. Other quality improvement measures in stroke, such as rehabilitation evaluation and treatment, stroke education, and smoking cessation counseling, were not evaluated. Fifth, these interventions are hospital-based, and adherence after hospital discharge can affect the benefits. Additional strategies should be considered to reduce secondary vascular events after discharge. 31 Sixth, leaving the hospital against medical advice is an important factor that affects outcomes of patients with stroke after discharge. This information was not recorded in this study. Seventh, imputing missing data on smoking as all "nonsmoking" is another limitation.
Conclusions
Among 40 hospitals in China, a multifaceted quality improvement intervention compared with usual care resulted in a statistically significant but small improvement in hospital personnel adherence to evidence-based performance measures in patients with acute ischemic stroke when assessed as a composite measure, but not as an all-or-none measure. Further research is needed to understand the generalizability of these findings. (Table 2) . Detailed performance measure specifications are shown in Table 3 . IV t-PA at an outside hospital, or who initiated IV t-PA after 180 minutes from onset.
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For performance measures at discharge, excludes patients who died during 214 hospitalization.
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Adherence is expressed as a composite measure or all-or-none measure. Web-based data capture system by a trained independent research coordinator who is 319 not involved in the care of patients with AIS. Range checks will be used for 320 inconsistent or out-of-range data and prompt the user to correct or review data entries 321 that outside the predefined range. The system also provides pre-defined logic checks 322 to identify erroneous, illogical data entries. A sample of 20% of all recruitments will 323 be selected at random and checked by research specialists from an independent 324 contract research organization (CRO) throughout the study period. Finally, a data 325 quality meeting will be held monthly to review all the hospital enrollment records and 326 registry data.
eAppendix. Details of the baseline survey
We conducted a baseline survey in participating clusters using the same eligible criteria for patient's inclusion (20 patients per cluster were prospectively included in this phase). This survey was conducted before randomization in order to avoid potential systematic errors caused by awareness of allocation to intervention and control groups. In all participating clusters, data were collected prospectively by a trained independent coordinator. Adherence to guidelines was assessed by a chart review, patient files, and physician prescriptions. Data were entered using a web-based data capture system as the same tool as that in the formal trial. The main objective of the baseline pre-randomization survey was to assess whether clusters were comparable with regard to baseline adherence to evidence-based performance measures and to obtain reliable estimates for our sample size estimation as reported in the main text. We used the same endpoint definition used in the randomized phase.
The composite measure was defined as the total number of interventions performed among eligible patients divided by the total number of possible interventions among eligible patients. There were no statistically significant differences between clusters that were later randomized to the intervention group and cluster later randomized to the control groups with respect to the composite measure of all eligible evidence-based performance measures. The composite measure of individual performance measures (intervention versus control group) was 80.2% versus 79.5%. Antihypertension medication prescribed at discharge for patients with history of hypertension disease or hypertension disease documented during the hospitalization Hypoglycemic therapy for diabetes mellitus Hypoglycemic medication prescribed at discharge for patients with history of diabetes mellitus or diabetes mellitus documented during the hospitalization Abbreviations: LDL, Low-density lipoprotein.
* Eligible patients are those without any medical contraindications (eg, treatment intolerance, excessive risk of adverse reaction, patient/family refusal, or terminal illness/comfort care only) documented as reasons for nontreatment for each of the applicable measures. Also excludes patients who are discharged to hospice or another short-term general hospital, leave against medical advice before the end of hospital day 2. For performance measures at the beginning of hospitalization except for rt-PA measure, excludes patients who died before the end of hospital day 2. The acute rt-PA
